HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

J. West, S. Ogston, J. Berg, C. Palmer, C. Fleming, V. Kumar, J. Foerster (Lead / Corresponding author)

Research output: Contribution to journalArticle

10 Citations (Scopus)
110 Downloads (Pure)

Abstract

It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA-Cw6 genotype status with treatment outcomes. HLA-Cw6+ patients showed notably improved response to methotrexate (P = 0.05), and further analysis demonstrated an even greater response in a subcohort of the HLA-Cw6+ patients, who did not have concomitant psoriatic arthritis (P = 0.01). HLA-Cw6+ patients also exhibited fewer treatment-limiting adverse events. In addition to these findings, the methodology and primary clinical outcome phenotype, which we validate here, will greatly facilitate replication of the present results in independent cohorts.

Original languageEnglish
Pages (from-to)651-655
Number of pages5
JournalClinical and Experimental Dermatology
Volume42
Issue number6
Early online date17 May 2017
DOIs
Publication statusPublished - 17 Jul 2017

Fingerprint

HLA Antigens
Psoriasis
Methotrexate
Therapeutics
Psoriatic Arthritis
Scotland
Age of Onset
Alleles
Genotype
Phenotype

Keywords

  • methotrexate
  • psoriasis
  • pharmacogenomics

Cite this

@article{486dabdc94d7434c97470ddca7d5a05c,
title = "HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment",
abstract = "It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA-Cw6 genotype status with treatment outcomes. HLA-Cw6+ patients showed notably improved response to methotrexate (P = 0.05), and further analysis demonstrated an even greater response in a subcohort of the HLA-Cw6+ patients, who did not have concomitant psoriatic arthritis (P = 0.01). HLA-Cw6+ patients also exhibited fewer treatment-limiting adverse events. In addition to these findings, the methodology and primary clinical outcome phenotype, which we validate here, will greatly facilitate replication of the present results in independent cohorts.",
keywords = "methotrexate, psoriasis, pharmacogenomics",
author = "J. West and S. Ogston and J. Berg and C. Palmer and C. Fleming and V. Kumar and J. Foerster",
note = "Funding: none.",
year = "2017",
month = "7",
day = "17",
doi = "10.1111/ced.13100",
language = "English",
volume = "42",
pages = "651--655",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",
publisher = "Wiley",
number = "6",

}

HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment. / West, J.; Ogston, S.; Berg, J.; Palmer, C.; Fleming, C.; Kumar, V.; Foerster, J. (Lead / Corresponding author).

In: Clinical and Experimental Dermatology, Vol. 42, No. 6, 17.07.2017, p. 651-655.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HLA-Cw6-positive patients with psoriasis show improved response to methotrexate treatment

AU - West, J.

AU - Ogston, S.

AU - Berg, J.

AU - Palmer, C.

AU - Fleming, C.

AU - Kumar, V.

AU - Foerster, J.

N1 - Funding: none.

PY - 2017/7/17

Y1 - 2017/7/17

N2 - It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA-Cw6 genotype status with treatment outcomes. HLA-Cw6+ patients showed notably improved response to methotrexate (P = 0.05), and further analysis demonstrated an even greater response in a subcohort of the HLA-Cw6+ patients, who did not have concomitant psoriatic arthritis (P = 0.01). HLA-Cw6+ patients also exhibited fewer treatment-limiting adverse events. In addition to these findings, the methodology and primary clinical outcome phenotype, which we validate here, will greatly facilitate replication of the present results in independent cohorts.

AB - It is well documented that patients with human leucocyte antigen (HLA)-Cw6+ (type 1) psoriasis have increased severity and reduced age of onset of psoriasis. However, not much is known about any differential response of this genetic subgroup to various treatments. We set out to determine if there was any genetic association of the HLA-Cw6 allele with the first-line systemic treatment commonly used in psoriasis, methotrexate. A cohort of patients from Tayside in Scotland was recruited through a novel generic consenting process (GoShare); they were extensively phenotyped and analysed for an association of their HLA-Cw6 genotype status with treatment outcomes. HLA-Cw6+ patients showed notably improved response to methotrexate (P = 0.05), and further analysis demonstrated an even greater response in a subcohort of the HLA-Cw6+ patients, who did not have concomitant psoriatic arthritis (P = 0.01). HLA-Cw6+ patients also exhibited fewer treatment-limiting adverse events. In addition to these findings, the methodology and primary clinical outcome phenotype, which we validate here, will greatly facilitate replication of the present results in independent cohorts.

KW - methotrexate

KW - psoriasis

KW - pharmacogenomics

U2 - 10.1111/ced.13100

DO - 10.1111/ced.13100

M3 - Article

VL - 42

SP - 651

EP - 655

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

IS - 6

ER -